Reference
- Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet 1998; 351: 1755–62
- UK Prospective Diabetes Study (UKPDS) Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317(7160): 703–13
- National Institutes of Health, National Heart, Lung, and Blood Institute, National High Blood Pressure Education Program. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. NIH publication No.98-4080, November 1997
- Flack JM, Hamaty M. Difficult-to-treat hypertensive populations: focus on African- Americans and people with type 2 diabetes. J Hypertens 1999; 17(Suppl 1):S19–24
- Teuscher AU, Weidmann PU. Requirements for antihypertensive therapy in diabetic patients: metabolic aspects. J Hypertens 1997; 15(Suppl 2):S67–75
- American Diabetes Association. Report of the expert committee on the diagnosis and classification of diabetes mellitus: clinical practice recommendations 2000. Diabetes Care 2000; 23(Suppl 1):S4–19
- Lewis EJ, Hunsicker LG, Bain RP, et al, for the Collaborative Study Group. The effect of angiotensin-converting- enzyme inhibition on diabetic nephropathy. N Engl J Med 1993; 329(20):1456–62
- Bakris GL, Mangrum A, Copley JB, et al. Effect of calcium channel or β-blockade on the progression of diabetic nephropathy in African Americans. Hypertension 1997; 29(3):744–50
- Bakris GL, Copley JB, Vicknair N, et al. Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy. Kidney Int 1996; 50(5):1641–50
- Chaiken RL, Palmisano J, Norton ME, et al. Interaction of hypertension and diabetes on renal function in black NIDDM subjects. Kidney Int 1995; 47(6): 1697–702
- Bakris G, White D. Effects of an ACE inhibitor combined with a calcium channel blocker on progression of diabetic nephropathy. J Human Hypertens 1997; 11:35–8
- Epstein M, Bakris G. Newer approaches to antihypertensive therapy: use of fixed-dose combination therapy. Arch Intern Med 1996; 156(17): 1969–78
- Bakris GL, Weir MR, DeQuattro V, et al. Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy. Kidney Int 1998; 54(4):1283–9
- Bretzel RG. Effects of antihypertensive drugs on renal function in patients with diabetic nephropathy. Am J Hypertens 1997; 10(9 Pt 2): 208S–17
- Rizzo JA, Robert-Simons W. Variations in compliance among hypertensive patients by drug class: implications for health care costs. Clin Ther 1997: 19(6): 1446–57
- Flack JM, Yunis C. Therapeutic implications of the epidemiology and timing of myocardial infarction and other cardiovascular diseases. J Human Hypertens 1997; 11:23–8
- Plat F, Saini R. Management of hypertension: the role of combination therapy. Am J Hypertens 1997; 10(Suppl): 262S–71
- Makrilakis K, Bakris G. Diabetic hypertensive patients: improving their prognosis. J Cardiovasc Pharmacol 1998; 31(Suppl 2):S34–40
- Schneider M, Lerch M, Papiri M, et al. Metabolic neutrality of combined verapamil-trandolapril treatment in contrast to beta blocker-low-dose chlortali-done treatment in hypertensive type 2 diabetes. J Hypertens 1996; 14:669–77